Drug Profile
Research programme: plectasin antibacterials - Adenium Biotech
Alternative Names: AP 114; AP 138Latest Information Update: 02 Feb 2018
Price :
$50
*
At a glance
- Originator Novozymes A/S
- Developer Adenium Biotech; Novozymes A/S
- Class Antibacterials; Peptides
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Clostridium difficile infections; Gram-positive infections
Most Recent Events
- 02 Feb 2018 Discontinued - Preclinical for Clostridium difficile infections in Denmark (IV) (Adenium Biotech pipeline, February 2018)
- 02 Feb 2018 Discontinued for Gram-positive infections in Denmark (unspecified route) (Adenium Biotech pipeline, February 2018)
- 28 Jan 2018 No recent reports of development identified for preclinical development in Clostridium-infections in Denmark (IV)